• General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis

Article

FDA requires additional phase 3 trial of Targanta antibiotic

Washington - The Food and Drug Administration (FDA) is requiring Targanta Therapeutics to conduct an additional phase 3 trial of its antibiotic oritavancin, according to fdanews.com.

Washington

- The Food and Drug Administration (FDA) is requiring Targanta Therapeutics to conduct an additional phase 3 trial of its antibiotic oritavancin, according to fdanews.com.

In order for oritavancin NDA to treat complicated skin and skin structure infections, the study must include subjects with methicillin-resistant Staphylococcus aureus, and several safety concerns must be addressed, including a high rate of participants dropping out due to lack of efficacy and serious adverse events, according to the release.

Related Videos
Ted Lain, MD, MBA, FAAD, is featured in this series.
Ted Lain, MD, MBA, FAAD, is featured in this series.
Ted Lain, MD, MBA, FAAD, is featured in this series.
E. James Song is featured in this video series.
E. James Song is featured in this video series.
© 2024 MJH Life Sciences

All rights reserved.